表紙
市場調査レポート

全身性エリテマトーデス:世界の治験レビュー

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 318809
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
全身性エリテマトーデス:世界の治験レビュー Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 128 Pages
概要

当レポートでは、全身性エリテマトーデスの臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどを提供しています。

イントロダクション

  • 全身性エリテマトーデス
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:P免疫疾患治療薬の治験における全身性エリテマトーデスの割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:P免疫疾患治療薬の治験における全身性エリテマトーデスの割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

全身性エリテマトーデス治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験のプロファイル

  • 主要企業の治験の概要
    • GlaxoSmithKline plc
    • AstraZeneca PLC
    • Human Genome Sciences, Inc. (Inactive)
    • F. Hoffmann-La Roche Ltd.
    • UCB S.A.
    • Pfizer Inc.
    • Immunomedics, Inc.
    • Teva Pharmaceutical Industries Limited
    • Immupharma Plc
    • Bristol-Myers Squibb Company
  • 代表的な研究機関・病院の治験の概要
    • National Institute of Arthritis and Musculoskeletal and Skin Diseases
    • National Center for Research Resources
    • Assistance Publique - Hopitaux de Paris
    • The National Institute of Allergy and Infectious Diseases
    • Johns Hopkins University
    • Oklahoma Medical Research Foundation
    • Duke University
    • Chinese University of Hong Kong
    • University of Sao Paulo
    • National Institute of Environmental Health Sciences

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2410CTIDB

GlobalData's clinical trial report, "Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014" provides data on the Systemic Lupus Erythematosus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Systemic Lupus Erythematosus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Systemic Lupus Erythematosus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Systemic Lupus Erythematosus
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Systemic Lupus Erythematosus
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Systemic Lupus Erythematosus Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Systemic Lupus Erythematosus
    • Oct 23, 2014: ABLYNX'S ANTI-IL-6R Nanobody Partnered With Abbvie Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection
    • Oct 02, 2014: Lilly to Discontinue Development Of Tabalumab Based On Efficacy Results In Phase 3 Lupus Studies
    • Sep 30, 2014: Lupuzor Gears Up To Start Pivotal Phase III trials
    • Sep 09, 2014: SuppreMol's clinical data in SLE for its lead product SM101 accepted for presentation at the 2014 ACR / ARHP Annual Meeting in Boston
    • Sep 08, 2014: Update on Invion's Phase II study of INV103 (ala-Cpn10) in lupus patients
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Human Genome Sciences, Inc. (Inactive)
      • Clinical Trial Overview of Human Genome Sciences, Inc. (Inactive)
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • UCB S.A.
      • Clinical Trial Overview of UCB S.A.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Immunomedics, Inc.
      • Clinical Trial Overview of Immunomedics, Inc.
      • Teva Pharmaceutical Industries Limited
      • Clinical Trial Overview of Teva Pharmaceutical Industries Limited
      • Immupharma Plc
      • Clinical Trial Overview of Immupharma Plc
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
    • Clinical Trial Overview of Top Institutes / Government
      • National Institute of Arthritis and Musculoskeletal and Skin Diseases
      • Clinical Trial Overview of National Institute of Arthritis and Musculoskeletal and Skin Diseases
      • National Center for Research Resources
      • Clinical Trial Overview of National Center for Research Resources
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • Johns Hopkins University
      • Clinical Trial Overview of Johns Hopkins University
      • Oklahoma Medical Research Foundation
      • Clinical Trial Overview of Oklahoma Medical Research Foundation
      • Duke University
      • Clinical Trial Overview of Duke University
      • Chinese University of Hong Kong
      • Clinical Trial Overview of Chinese University of Hong Kong
      • University of Sao Paulo
      • Clinical Trial Overview of University of Sao Paulo
      • National Institute of Environmental Health Sciences
      • Clinical Trial Overview of National Institute of Environmental Health Sciences
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Region, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Systemic Lupus Erythematosus Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Human Genome Sciences, Inc. (Inactive), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by UCB S.A., 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Immupharma Plc, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Oklahoma Medical Research Foundation, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Environmental Health Sciences, 2014*

List of Figures

  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials, G7 Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials, E7 Countries (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Systemic Lupus Erythematosus Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Systemic Lupus Erythematosus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top